![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ABCG5 |
Gene summary for ABCG5 |
![]() |
Gene information | Species | Human | Gene symbol | ABCG5 | Gene ID | 64240 |
Gene name | ATP binding cassette subfamily G member 5 | |
Gene Alias | STSL | |
Cytomap | 2p21 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q9H222 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64240 | ABCG5 | NAFLD1 | Human | Liver | NAFLD | 1.07e-09 | 9.06e-01 | -0.04 |
64240 | ABCG5 | S41 | Human | Liver | Cirrhotic | 2.93e-02 | 3.07e-01 | -0.0343 |
64240 | ABCG5 | S43 | Human | Liver | Cirrhotic | 2.84e-02 | -1.04e-01 | -0.0187 |
64240 | ABCG5 | HCC1_Meng | Human | Liver | HCC | 2.82e-08 | -8.45e-02 | 0.0246 |
64240 | ABCG5 | HCC1 | Human | Liver | HCC | 1.34e-13 | 3.56e+00 | 0.5336 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00550883 | Liver | NAFLD | lipid homeostasis | 44/1882 | 167/18723 | 1.48e-09 | 2.54e-07 | 44 |
GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
GO:00316677 | Liver | NAFLD | response to nutrient levels | 85/1882 | 474/18723 | 8.23e-08 | 7.09e-06 | 85 |
GO:0055090 | Liver | NAFLD | acylglycerol homeostasis | 17/1882 | 42/18723 | 2.22e-07 | 1.53e-05 | 17 |
GO:0070328 | Liver | NAFLD | triglyceride homeostasis | 17/1882 | 42/18723 | 2.22e-07 | 1.53e-05 | 17 |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00303013 | Liver | NAFLD | cholesterol transport | 30/1882 | 117/18723 | 1.08e-06 | 5.40e-05 | 30 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
GO:00159183 | Liver | NAFLD | sterol transport | 32/1882 | 130/18723 | 1.27e-06 | 6.01e-05 | 32 |
GO:00426323 | Liver | NAFLD | cholesterol homeostasis | 26/1882 | 96/18723 | 1.83e-06 | 7.86e-05 | 26 |
GO:00550923 | Liver | NAFLD | sterol homeostasis | 26/1882 | 97/18723 | 2.26e-06 | 9.51e-05 | 26 |
GO:0033344 | Liver | NAFLD | cholesterol efflux | 20/1882 | 69/18723 | 9.13e-06 | 2.98e-04 | 20 |
GO:00075844 | Liver | NAFLD | response to nutrient | 36/1882 | 174/18723 | 2.06e-05 | 5.78e-04 | 36 |
GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
GO:0032371 | Liver | NAFLD | regulation of sterol transport | 20/1882 | 78/18723 | 6.46e-05 | 1.39e-03 | 20 |
GO:0032374 | Liver | NAFLD | regulation of cholesterol transport | 20/1882 | 78/18723 | 6.46e-05 | 1.39e-03 | 20 |
GO:19044781 | Liver | NAFLD | regulation of intestinal absorption | 7/1882 | 13/18723 | 1.02e-04 | 2.02e-03 | 7 |
GO:0030300 | Liver | NAFLD | regulation of intestinal cholesterol absorption | 6/1882 | 10/18723 | 1.50e-04 | 2.78e-03 | 6 |
GO:1905952 | Liver | NAFLD | regulation of lipid localization | 34/1882 | 181/18723 | 2.51e-04 | 4.12e-03 | 34 |
GO:19047291 | Liver | NAFLD | regulation of intestinal lipid absorption | 6/1882 | 11/18723 | 3.03e-04 | 4.75e-03 | 6 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049796 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa02010 | Liver | NAFLD | ABC transporters | 16/1043 | 45/8465 | 4.97e-05 | 1.16e-03 | 9.37e-04 | 16 |
hsa049762 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
hsa0497911 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa020101 | Liver | NAFLD | ABC transporters | 16/1043 | 45/8465 | 4.97e-05 | 1.16e-03 | 9.37e-04 | 16 |
hsa0497611 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
hsa049792 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa049793 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa020102 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa020103 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABCG5 | SNV | Missense_Mutation | c.1078N>C | p.Asp360His | p.D360H | Q9H222 | protein_coding | deleterious(0) | possibly_damaging(0.541) | TCGA-49-6745-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | SD | |
ABCG5 | SNV | Missense_Mutation | c.962N>C | p.Arg321Thr | p.R321T | Q9H222 | protein_coding | deleterious(0) | possibly_damaging(0.617) | TCGA-49-6745-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | SD | |
ABCG5 | SNV | Missense_Mutation | c.1214N>C | p.Leu405Pro | p.L405P | Q9H222 | protein_coding | deleterious(0.02) | probably_damaging(0.947) | TCGA-55-7994-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR | |
ABCG5 | SNV | Missense_Mutation | rs376129056 | c.595N>T | p.Arg199Cys | p.R199C | Q9H222 | protein_coding | deleterious(0.03) | benign(0.156) | TCGA-55-8089-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ABCG5 | SNV | Missense_Mutation | c.1356N>C | p.Glu452Asp | p.E452D | Q9H222 | protein_coding | deleterious(0) | possibly_damaging(0.817) | TCGA-62-8399-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ABCG5 | SNV | Missense_Mutation | c.234N>A | p.Ser78Arg | p.S78R | Q9H222 | protein_coding | deleterious(0.04) | probably_damaging(0.973) | TCGA-67-4679-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ABCG5 | SNV | Missense_Mutation | novel | c.1504N>G | p.Phe502Val | p.F502V | Q9H222 | protein_coding | deleterious(0) | possibly_damaging(0.666) | TCGA-75-5147-01 | Lung | lung adenocarcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ABCG5 | SNV | Missense_Mutation | rs143402711 | c.1411N>A | p.Val471Ile | p.V471I | Q9H222 | protein_coding | tolerated(1) | benign(0.001) | TCGA-86-8672-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ABCG5 | SNV | Missense_Mutation | novel | c.534N>G | p.Ser178Arg | p.S178R | Q9H222 | protein_coding | tolerated(0.2) | possibly_damaging(0.549) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ABCG5 | SNV | Missense_Mutation | c.642G>A | p.Met214Ile | p.M214I | Q9H222 | protein_coding | tolerated(0.34) | benign(0.063) | TCGA-97-7937-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |